2018 Meet-The-Professor Endocrine Case Management

Meet-The-Professor Case Management is designed to provide physicians with a concise and high-quality review of over 60 common and rare endocrine disorders to help you keep your practice current. It consists of case-based clinical cases and rationale by experts in all areas of endocrinology, diabetes, and metabolism.

You must first purchase this through our online store. Once you have completed your purchase you will receive access to this CME activity.

Visit the Online Store to purchase today.

Target Audience

Meet-The-Professor Case Management provides case-based education to clinicians interested in improving patient care.

Learning Objectives

Meet-The-Professor Case Management will allow learners to assess their knowledge of all aspects of endocrinology, diabetes, and metabolism.

Upon completion of this educational activity, learners will be able to:

  • Recognize clinical manifestations of endocrine and metabolic disorders and select among current options for diagnosis, management, and therapy.
  • Identify risk factors for endocrine and metabolic disorders and develop strategies for prevention.
  • Evaluate endocrine and metabolic manifestations of systemic disorders.
  • Use existing resources pertaining to clinical guidelines and treatment recommendations for endocrine and related metabolic disorders to guide diagnosis and treatment.

Additional Information

Target Audience: 
Clinical researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Quality Improvement and Healthcare Delivery
General Endocrinology
Hormone Abuse
Growth Disorders
Health Disparities
Hormones and Cancer
Men’s Health
Neuroendocrinology and Pituitary
Pediatric Endocrinology
Thyroid/HPT Axis
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 30.00 AMA PRA Category 1 Credits
  • 30.00 CME Certificate of Participation
Course opens: 
Course expires: 
99.00 / e-book $79.00
79.00 / e-book $59.00
In-Training Member
59.00 / e-book $39.00

2018 Meet-The-Professor Case Management Faculty

Robert Adler, MD
McGuire Veterans Affairs Medical Center

S Faisal Ahmed, MD, FRCPCH
Royal Hospital for Children

Bradley Anawalt, MD
University of Washington

Simon Aylwin, MA, MB, BChir, PhD, FRCP
King's College Hospital

Irina Bancos, MD
Mayo Clinic

Daniel Bichet, MD
Universite de Montreal

Jeffrey Boord, MD, MPH
Parkview Health

Pierre-Marc Bouloux, BSC, MD, FRCP
Royal Free Hospital

Gregory Brent, MD
UCLA David Geffen School of Medicine

Rebecca Brown, MD
National Institutes of Health

Paul Carroll, MD
Guy's & St Thomas' NHS Foundation Trust

Frederic Castinetti, MD, PhD
La Conception Hospital

Laurie Cohen, MD
Boston Children's Hospital

Ellen Connor, MD
University of Wisconsin Hospital

Natalie Cusano, MD, MS
Lenox Hill Hospital

Ramona Dadu, MD
The University of Texas MD Anderson Cancer Center

Jaime Davidson, MD
The University of Texas Southwestern Medical Center

Jaydira Del Rivero, MD
National Cancer Institute/NIH

Sara DiVall, MD
University of Washington

Gerard Doherty, MD
Harvard Medical School

Henry Dufour, MD
University de la Méditerranée

Richard Dunbar, MD
University of Pennsylvania

Richard Eastell, MD
University of Sheffield

Peter Ebeling, AO
Monash University

David Ehrmann, MD
University of Chicago

Lauren Fishbein, MD, PhD
University of Colorado School of Medicine

Peter Gaede, MD
Slagelse Sygehus

Anne Goldberg, MD
Washington University School of Medicine

Steven Grinspoon, MD
Massachusetts General Hospitalital

Ashley Grossman, MD, FRCP
Royal Free London

Mark Gurnell, PhD, MA(Medicine), FHEA, FAcadMedicine, FRCP
University of Cambridge

Stephanie Hahner, MD
University Hospital of Wuerzburg

Gary Hammer, MD, PhD
University of Michigan

Niki Karavitaki, FRCP
University of Birmingham

Laurence Katznelson, MD
Stanford University

Susan Kirk, MD
University of Virginia

Karen Klein, MD
Children's Hospital and Health Center

Bente Langdahl, DMSc
Aarhus University Hospitalital

John (Jack) Leahy, MD
University of Vermont College of Medicine

Jonathan Leffert, MD
North Texas Endocrine Center

Michael Levine, MD
Children's Hospital of Philadelphia

Susan Mandel, MD, MPH
University of Pennsylvania

Kathryn Martin, MD
Massachusetts General Hospital

Barbara McGowan, MBBS, PhD
Guy's & St. Thomas's NHS Trust

John Miell, MD, DM, FRCPE, FRCP
Lewisham Healthcare

Mark Molitch, MD
Northwestern University

Lisa Neff, MD
Northwestern University

Mary Patti, MD
Joslin Diabetes Center

Anne Peters, MD
University of Southern California

Vera Popovic-Brkic, MD, PhD
University of Belgrade

Richard Quinton, MD, FRCP
University of Newcastle-upon-Tyne

Jane Reusch, MD
Denver Veterans Affairs Medical Center

Scott Rivkees, MD
University of Florida

Richard Ross, MBBS, MD, FRCP
University of Sheffield

Micol Rothman, MD
University of Colorado Denver

Elizabeth Seaquist, MD
University of Minnesota

Mark Sherlock, MB, BCh, BAO, MRCPI
Tallaght Hospital

Mark Sperling, MD
Mount Sinai School of Medicine

Antoine Tabarin, MD
University de Bordeaux

Lisa Tannock, MD
University of Kentucky

Peter Trainer, MD
The Christie NHS Foundation Trust

Guillermo Umpierrez, MD
Emory University School of Medicine

Joseph Verbalis, MD
Georgetown University

W Edward Visser, MD, PhD
Erasmus Medical Center

Steven Waguespack, MD
University of Texas

John Wass, MD
Churchill Hospital

Margaret Wierman, MD
University of Colorado School of Medicine

Teresa Woodruff, PhD
Northwestern University


John Newell-Price, MA, PhD, FRCP, ENDO 2018 Chair
University of Sheffield

Samuel Dagogo-Jack, MD, MBBS, Clinical Science Chair
University of Tennessee Health Science Center

Ann Danoff, MD, Physician-In-Practice Chair
University of Pennsylvania

Annual Meeting Steering Committee Clinical Peer Reviewers
Guillaume Assié, MD, PhD; Felix Beuschlein, MD; Lisa S. Chow, MD; Mark Cooper, BM, BCH, PhD, FRCP, FRACP; David A. D'Alessio, MD; Matthew T. Drake, MD, PhD; Maralyn Druce, MA, MBBS, FRCP, PhD, MMed, SFHEA; Robert Eckel, MD; Richard A. Feelders, MD, PhD; Larry A. Fox, MD; Megan R. Haymart, MD; Anders Juul, MD, PhD, DMSC; Lawrence S. Kirschner, MD, PhD; Peter Kopp, MD; Ana Luiza Maia, MD, PhD; Sally Radovick, MD; Stephanie B. Seminara, MD; Nalini Shah, DM; Adrian Vella, MD, FRCP; Bulent Yildiz, MD

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Annual Meeting Steering Committee.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers’ bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivering content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationship(s): The following faculty reported relevant financial relationships, as identified below:

L.E. Cohen: is a study site principal investigator for Versartis, Ascendis, and Opko; and received an honorarium from Scherer Clinical Communications, which received grant support from Novo Nordisk. N.E. Cusano: is a member of the speakers’ bureau of Shire. R. Dadu: serves on the advisory board of Bristol-Myers Squibb. Consulting fee, Eisai. R.L. Dunbar: serves on the advisory board of Akcea Therapeutics; received grant support from Akcea Therapeutics, AstraZeneca, Amarin, Zydus, Regeneron, and Kowa. A.C. Goldberg: serves on the advisory board of Esperion, Regeneron Pharmaceuticals, and Sanofi; is a consultant for OptumRX; is a research investigator for Ionis Pharmaceuticals Inc., Amgen Inc, Pfizer, Inc., Sanofi, Regeneron Pharmaceuticals, and Amarin.; and serves as editor of the Merck Manual. G.D. Hammer: is a consultant for HRA Pharmaceuticals, Millendo Therapeutics, Orphagen, and Embara; is an owner of Millendo Therapeutics; owns stock in Millendo Therapeutics, HRA Pharmaceuticals, and Embara. B.L. Langdahl: serves on the advisory board of Amgen Inc, UCB Pharmaceuticals, and Eli Lilly; receives grant support from Novo Nordisk; is a research investigator for Amgen Inc and Mereo; and is a member of the speakers’ bureau of Amgen Inc, Eli Lilly & Company, Teva Pharmaceutical Industries Ltd., and UCB Pharmaceuticals. J.L. Leahy: serves on the advisory board of Novo Nordisk, Merck & Co., Sanofi, Valeritas, Janssen Research & Development Company; and is a member of the speakers’ bureau of Merck. M.E. Molitch: is a consultant for Merck, Pfizer, Inc., Novartis Pharmaceuticals, Chiasma; receives grant support from Bayer, Inc., Novartis Pharmaceuticals, Novo Nordisk, Chiasma, and Jansen Pharmaceuticals; and his spouse owns stock in Amgen Inc. M.E. Patti: is a consultant for Eiger; receives grant support from Jansen Pharmaceuticals, Medimmune, and Xeris Pharmaceuticals; and is a research investigator for XOMA. A. Peters: serves on the advisory board of Abbott Laboratories, Boehringer Ingelheim, Eli Lilly & Company, Lexicon Pharmaceuticals, Inc., Merck, Novo Nordisk, and Sanofi; is a research investigator for Mannkind Corporation; and is a member of the speakers’ bureau of Eli Lilly & Company, and Dexcom. R.J. Ross: owns stock in Diurnal. E.R. Seaquist: is a consultant for Eli Lilly & Company, Medtronic Diabetes, Novo Nordisk, and Sanofi; serves on the advisory board of Zucara; and is consultant for 360 Marketing Services. P.J. Trainer: is a consultant for Strongbridge; serves on the advisory board of Versartis, Chiasma, Novartis Pharmaceuticals, Ipsen, ONO-Pharma, and Antisense Pharmaceuticals; and is a research investigator for Novartis Pharmaceuticals. G.E. Umpierrez: received grant support from Aventis Pharmaceuticals, Novo Nordisk, Merck, AstraZeneca, and Boehringer Ingelheim. J.G. Verbalis: serves on the advisory board of Corcept; and is a consultant for Ferring Pharmaceuticals and Otsuka. W.F. Young: is a consultant for Nihon Medi-Physics.

The following faculty reported no relevant financial relationships: R. Adler; B. Anawalt; S. Aylwin; I. Bancos; J. Boord ; P-M Bouloux; G. Brent; R. Brown; F. Castinetti; E. Connor; J. Del Rivero; S. DiVall; G. Doherty; H. Dufour; R. Eastell; D. Ehrmann; L. Fishbein; P. Gaede; A. Gharib; M. Gurnell; S. Hahner; S. Kirk; M. Levine; S. Mandel; J. Miell; L. Neff; V. Popovic-Brkic; R. Quinton; S. Rivkees; M. Sherlock; L. Tannock; W.E. Visser; S. Waguespack; J. Wass; M. Wierman; T. Woodruff.

The following AMSC peer reviewers reported relevant financial relationship(s): G. Assié: Speaker, Novartis; F. Beuschlein: Speaker, Ipsen, HRA Pharma; L.S. Chow: Grant support, Eli Lilly, Medtronics; S. Dagogo-Jack: Principal Investigator/Co-investigator for Clinical Trials Contracts to University of Tennessee from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Consultant , Amgen, Merck, Sanofi, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janacare, Janssen, Perle Bioscience, Response Scientific, Inc.; Stock Owner: Dance Pharma, Janacare; D.A. D'Alessio: Consultant, Lilly, Merck, Janssen, Intarcia, Novo Nordisk, Grant Suport, Merck; M. Drake: serves on the advisory board for Amgen and Ultragenyx; M.R. Druce: Advisory Board, Ipsen; R. Eckel: Consultant, Sanofi Aventis, Regeneron Pharmaceuticals, Novo Nordisk - Scientific Advisor; R.A. Feelders: Grant support, Novartis, Ipsen; Juul, Anders: Speaker, Novo Nordisk, Pfizer, Ferring, Merck, Bayer; Clinical Trial; J.D.C. Newell-Price: The Pituitary Foundation (Patient support charity) Trustee; Advisory Board Member, Novartis, Ipson, HRA Pharma; Partridge, Nicola C: Consultant and Research Contract, Orthofix, Inc.; S. Radovick: Consultant, CVS Caremark; Support, NESGAS, PORIYA; L.S. Kirschner: Advisory Board, Corcept Therapeutic; A.V. Vella: Principal Investigator, Novo Nordisk, Obesity Society, XOMA, Member of Advisory Board, VTV Therapeutics.

The following AMSC peer reviewers reported no relevant financial relationships: M.S. Cooper; A. Danoff; L.A. Fox; M.R. Haymart; P. Kopp; S.B. Seminara; N.S. Shah; B.O. Yildiz.

The medical editor for this program reported no relevant financial relationships.

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

The educational content in this enduring activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

This activity is not supported by educational grant(s) or other funds from any commercial supporter.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this activity for a maximum of 30.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is presented in print format. The estimated time to complete this activity, including review of material, is 30 hours. Participants must achieve a minimum score of 70% to claim CME credit. After initially completing the module, if participants do not achieve a minimum score of 70%, they have the option to change their answers and make additional attempts to achieve a passing score. Participants also have the option to clear all answers and start over.

Available Credit

  • 30.00 AMA PRA Category 1 Credits
  • 30.00 CME Certificate of Participation

Course closed

This course closed on Tuesday, March 31, 2020 - 11:59pm.

You must first purchase this through our online store. Once you have completed your purchase you will receive access to this CME activity.

Visit the Online Store to purchase today.